Advertise on podcast: JAMA Medical News

AI in clinical practice needs ethical frameworks to avert future biases. In this Q&A, Marzyeh Ghassemi, PhD, the Herman L. F. von Helmholtz Career Development Professor at MIT in Electrical Engineering and Computer Science (EECS), joins JAMA's Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss ethical machine learning and responsible clinical implementation. Related Content: AI Developers Should Understand the Risks of Deploying Their Clinical Tools, MIT Expert Says

What the Latest Research Says About Paxlovid; People Are Using Potentially Dangerous “Trip-Killers” to Counter Psychedelics; Social Media Affects Youth Mental Health—Here’s What Could Help Related Content: Paxlovid Is Effective but Underused—Here’s What the Latest Research Says About Rebound and More Study Finds Hundreds of Reddit Posts on “Trip-Killers” for Psychedelic Drugs Social Media Industry Standards Needed to Protect Adolescent Mental Health, Says National Academies

How can we leverage AI to transform health care into a more efficient model for delivering care? In this Q&A, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, interviews Atul Butte, MD, PhD, the director of the Bakar Computational Health Sciences Institute at UCSF, to discuss scalable privilege and the need for the broad distribution of AI-driven expertise. Related Content: “Scalable Privilege”—How AI Could Turn Data From the Best Medical Systems Into Better Care for All

After a Decade, Goodbye to the Pooled Cohort Equations? Experts Tackle Racial Bias in Clinical Algorithms; How COVID-19 Might Be Tied to Other Respiratory Disease Outbreaks Related Content: What to Know About PREVENT, the AHA’s New Cardiovascular Disease Risk Calculator Citing Harms, Momentum Grows to Remove Race From Clinical Algorithms From “Immunity Debt” to “Immunity Theft”—How COVID-19 Might Be Tied to Recent Respiratory Disease Surges

Amid the surging buzz around artificial intelligence (AI), can we trust the Al hype, and more importantly, are we ready for its implications? In this Q&A, Arvind Narayanan, PhD, a professor of computer science at Princeton, joins JAMA's Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the exploration of Al's fairness, transparency, and accountability. Related Content: How to Navigate the Pitfalls of AI Hype in Health Care

The Next Generation of COVID-19 Vaccines May Be Inhaled; Does Paxlovid Prevent Long COVID? Apply to the Morris Fishbein Fellowship in Medical Editing. Related Content: Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19 Vaccines Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID The Morris Fishbein Fellowship in Medical Editing

Artificial intelligence holds the promise of revolutionizing disease diagnosis and prediction, but it also presents a pivotal challenge: ensuring equity. In this Q&A, Alondra Nelson, PhD, the Harold F. Linder Professor at the Institute for Advanced Study, joins JAMA's Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the equitable regulation of AI to benefit all populations. Related Content: How Do Policymakers Regulate AI and Accommodate Innovation in Research and Medicine?

In this Q&A, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, interviews John Ayers, PhD, MA, vice chief of innovation in the Division of Infectious Diseases & Global Public Health, deputy director of informatics in the Altman Clinical and Translational Research Institute, and affiliate scientist in the Qualcomm Institute, all at UC San Diego, to discuss how genAI programs like ChatGPT can increase communication pathways and improve patient outcomes. Related Content: How AI Assistants Could Help Answer Patients’ Messages—and Potentially Improve Their Outcomes

Why Physicians Don’t Deprescribe Medicines; What to Know About Wegovy’s Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug Related Content: As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management Deciding When It’s Better to Deprescribe Medicines Than to Continue Them

JAMA Associate Editor Gregory Marcus, MD, a cardiologist and professor of medicine at the University of California San Francisco, speaks with American Heart Association Scientific Sessions 2023 conference chair Amit Khera, MD, MSc, a professor in the department of internal medicine at UT Southwestern Medical Center and the director of preventive cardiology. Related Content: Highlights From AHA 2023—New Risk Calculator, Semaglutide and CVD, and More

In this Q&A, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, interviews Nigam Shah, MBBS, PhD, professor of medicine at Stanford University and chief data scientist at Stanford Health Care, to discuss how large language models are reshaping medicine and the potential pitfalls of automation. Related Content: Clinical AI Tools Must Be Fed the Right Data, Stanford Health Care's Chief Data Scientist Says Creation and Adoption of Large Language Models in Medicine

New vaccines, artificial intelligence, antimicrobial resistance, and more—JAMA Deputy Editor Preeti Malani, MD, MSJ, speaks with IDWeek 2023 cochair Col Heather Yun, USAF, MC. The infectious disease physicians discuss clinical highlights from the conference. Related Content: Highlights From IDWeek 2023—New Vaccines, Artificial Intelligence, and Antimicrobial Resistance